

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6066835

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	APOTEX INC.	01/08/2020
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	CHIESI FARMACEUTICI S.P.A.	
<b>Street Address:</b>	VIA PALERMO 26/A	
<b>City:</b>	PARMA	
<b>State/Country:</b>	ITALY	
<b>Postal Code:</b>	43122	
<b>PROPERTY NUMBERS Total: 1</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	16839928	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	2023712600	
<b>Email:</b>	bncombs@sternekessler.com, jmccoy@sternekessler.com, jyando@sternekessler.com, ttopssecretary2@sternekessler.com	
<b>Correspondent Name:</b>	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.	
<b>Address Line 1:</b>	1100 NEW YORK AVENUE NW	
<b>Address Line 4:</b>	WASHINGTON, D.C. 20005	
<b>ATTORNEY DOCKET NUMBER:</b>	4559.0090006	
<b>NAME OF SUBMITTER:</b>	BONNIE W. NANNENGA-COMBS, REG. NO. 67836	
<b>SIGNATURE:</b>	/Bonnie W. Nannenga-Combs/	
<b>DATE SIGNED:</b>	04/17/2020	
<b>Total Attachments: 6</b>		
source=To Be recorded - Assignment-Apotex to Chiesi 4559.0090006#page1.tif		
source=To Be recorded - Assignment-Apotex to Chiesi 4559.0090006#page2.tif		
source=To Be recorded - Assignment-Apotex to Chiesi 4559.0090006#page3.tif		
source=To Be recorded - Assignment-Apotex to Chiesi 4559.0090006#page4.tif		
source=To Be recorded - Assignment-Apotex to Chiesi 4559.0090006#page5.tif		



## PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT dated as of January 8, 2020 (this “**Assignment**”) is by and between Apotex Inc. (“**Assignor**”) and Chiesi Farmaceutici S.p.A. (“**Assignee**”).

### W I T N E S S E T H:

WHEREAS, Assignor, Apo-Pharma USA, Inc., and Assignee have entered into an Asset Purchase Agreement, dated as of October 29, 2019 (as amended, the “**Purchase Agreement**”), pursuant to which, among other things, Assignor has agreed to sell or cause to be sold certain assets to Assignee (or one or more of its Affiliates), as more fully described in the Purchase Agreement and upon the terms and conditions set forth therein; and

WHEREAS, pursuant to the Purchase Agreement, Assignor wishes to assign to Assignee, and Assignee wishes to assume from Assignor, the Purchased Patent that are listed on Schedule A.

NOW, THEREFORE, in consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and upon the terms and subject to the conditions set forth herein, the parties hereto hereby agree as follows:

1. Definitions. Capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Purchase Agreement.

2. Assignment. Assignor hereby irrevocably and unconditionally grants, sells, transfers, conveys, assigns and delivers to Assignee all of Assignor’s right, title and interest in and to the Purchased Patents that are listed on Schedule A, together with all rights and remedies related to past, present and future infringement thereof and rights to protection of interests related thereto under all applicable laws. Assignor hereby authorizes the respective patent office or Governmental Authority in each jurisdiction to issue any and all patents, certificates of invention, utility models or other governmental grants or issuances that may be granted upon any of the Purchased Patents that are listed on Schedule A in the name of Assignee, as the assignee to the entire interest therein. Assignor further consents to the recordation of this Assignment by Assignee with the respective patent office or Governmental Authority in each jurisdiction.

3. No Modification of the Purchase Agreement. Nothing contained herein shall release Assignor or Assignee from any of their respective obligations under the Purchase Agreement or in any way supersede, enlarge, diminish, limit, amend or modify any of the representations, warranties, indemnities, covenants or agreements of such parties set forth in the Purchase Agreement. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern.

4. General Provisions. Sections 1.2 (Construction), 10.1 (Governing Law, Jurisdiction, Venue and Service), 10.2 (Notices), 10.3 (No Benefit to Third Parties), 10.4 (Waiver and Non-Exclusion of Remedies), 10.5 (Expenses), 10.6 (Assignment), 10.7 (Amendment), 10.8 (Severability), 10.9 (Equitable Relief), 10.10 (English Language), 10.11 (Bulk Sales Statutes) and 10.12 (Counterparts) of the Purchase Agreement are each hereby incorporated by reference herein *mutatis mutandis*.

[Signature Page Follows]

IN WITNESS WHEREOF, Assignor and Assignee have executed this instrument as of the date and year first written above.

APOTEX INC.

By: 

Name: JEFF WATSON

Title: PRESIDENT & CEO

IN WITNESS WHEREOF, Assignor and Assignee have executed this instrument as  
of the date and year first written above.

**CHIESI FARMACEUTICI S.P.A.**

By:   
Name: Giacomo Chiesi  
Title: Head of Global Corporate Development

*[Signature Page to Patent Assignment - Apotex Inc.]*



Title:	DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME
Filing Date:	10/25/2018
Inventors:	Sherman and Spino
	U.S. Non Provisional Utility Patent Application

Client Reference No	Country	Title	Owner	Status	Patent Application No.	Patent No.	Validated Countries
3154.0090004	United States	DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME	Apotex Inc		16/171,173	N/A	N/A

Title:	DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME
Filing Date:	10/25/2018
Inventors:	Sherman and Spino
	U.S. Non Provisional Utility Patent Application (Track 1)

Client Reference No.	Country	Title	Owner	Status	Patent Application No.	Patent No.	Validated Countries
3154.0090004	United States	DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME	Apotex Inc		16/171,170	N/A	N/A
3154.0090005	United States	DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAME	Apotex Inc.		16/714,520	N/A	N/A

Tot#: 9316699.6

Schedule A-10